• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most Read Stories This Week—June 25

    Magnetic Insight Announces $17 Million in Series B Funding

    BreatheSuite Adds Brad Fluegel to its Board

    Labcorp Launches At-Home Collection Device for Diabetes Risk Testing

    Thirona, Free Flow Medical Partner on COPD Solutions
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    OEMs Seek Molders Offering Timely Techniques

    Robotic Surgery: Cutting Through to the Latest

    Packaging, Sterilization Considerations Go Part and Parcel with Product Development

    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Theranos Fraud Trial, Part II: The Blame Game Continues

    An Update on Surgical Robotics

    Letting the Light In: How Failure Analysis is the Cornerstone of Success

    Three Talent Strategies to Attract High-Demand Skills

    The Advantages of Bioburden Screening for Sterilization Validation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Fusion Biotec Inc.

    BMP Medical

    Trademark Plastics Inc.

    Cirtec Medical

    Concise Engineering
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    The Power of Leveraging Customer Relationships

    Cost Effective & Efficient Wire EDM Techniques

    How MedTech Professionals Can Help Combat Physician Burnout

    How to Optimize Manufacturing Lines and Choose Which Machines to Buy

    How Are Hypodermic Needles Made?
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Fusion Biotec Inc.

    BMP Medical

    Trademark Plastics Inc.

    Cirtec Medical

    Concise Engineering
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Helius Announces Positive Results from Portable Neuromodulation Stimulator Trial

    The registrational trial was evaluating the safety and effectiveness of the device for treatment related to TBI.

    Helius Announces Positive Results from Portable Neuromodulation Stimulator Trial
    Helius’ Portable Neuromodulation Stimulator would be indicated for the treatment of subjects with chronic balance deficits due to mild-to-moderate TBI.
    Related CONTENT
    • Breakthrough Device Designation Granted for New Neuromodulation Platform
    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    • Improved Outcomes Proven With Insulet’s Omnipod 5 System
    • Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe
    • Vertigo Treatment Receives FDA Breakthrough Device Designation
    Globe Newswire11.22.17
    Helius Medical Technologies Inc., a medical technology company focused on neurological wellness, announced results from its registrational trial evaluating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS) for the treatment of subjects with chronic balance deficits due to mild-to-moderate TBI.
     
    The multi-center registrational trial titled, A double-blind, randomized, sham-controlled study of the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS) 4.0 device for cranial nerve noninvasive neuromodulation (CN-NINM) training in subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI), evaluated a total of 122 randomized subjects (61 active and 61 control). Subjects, age 18 to 65, received 5 weeks of treatment (2 weeks in-clinic and 3 weeks at-home) consisting of physical therapy and either a high-frequency PoNS device (active) or a low-frequency PoNS device (control).
     
    Endpoints for effectiveness were assessed using the Sensory Organization Test (SOT), measuring balance using computerized dynamic posturography. A responder rate analysis was used for the primary endpoint. A responder was defined as a subject with an improvement of at least 15 points on the composite SOT score compared to baseline after 5 weeks of PoNS Therapy.
     
    Secondary effectiveness endpoints were contingent on the outcome of the primary endpoint and determining the clinical effectiveness of the low-frequency device. As the low-frequency device demonstrated, on average, statistically significant improvements on composite SOT scores compared to baseline (p<0.025)—the secondary effectiveness endpoints evaluated for the study were the mean change in composite SOT score from baseline at 2 and 5 weeks, for both arms combined.
     
    Endpoints for safety were assessed by frequency of falls, frequency of headaches, and Adverse Events (AEs). Falls and headaches were measured by daily activity logs and the Headache Disability Index, respectively.
     
    Study results highlights:
     
    • Primary effectiveness endpoint demonstrated a trend toward a higher responder rate in the high frequency PoNS Therapy group (75.4 percent) than in the low frequency PoNS Therapy group (60.7 percent), p<0.081
      • Primary effectiveness endpoint was not reached because low frequency pulse treatment had a significant therapeutic effect
    • Secondary effectiveness endpoints demonstrated statistically and clinically significant increases (at least 8 points) in composite SOT scores:
      • The mean improvement at 2 weeks for combined-arms was 18.3 points, p<0.0005
      • The mean improvement at 5 weeks for combined-arms was 24.6 points, p<0.0005
    • Successfully met primary and secondary safety endpoints as measured by a decrease in falls and headaches, in both groups
    • There were no serious device related adverse events
     
    “We are very pleased with the findings from our registrational trial that demonstrate that PoNS Therapy, deployed independently across our seven study sites, produced statistically significant improvements in balance from baseline, on average over three times the clinically significant amount,” said Dr. Jonathan Sackier, Helius’ chief medical officer. “Achieving the safety endpoints and further growing a positive safety profile continues to build confidence in our technology. With an underserved patient population waiting for improved treatment opportunities, we are eager to move forward with our applications for clearance with the U.S. Food and Drug Administration (FDA) and other foreign regulatory bodies.”
     
    TBI is a serious public health problem in the United States, according to the U.S. Center for Disease Control. A large proportion of TBI patients with chronic balance symptoms are left with limited treatments options. Currently available therapies are minimally effective and focus on teaching patients how to cope with their remaining deficits, rather than improving symptoms.
     
    “We are excited to be on the forefront of research that may bring this novel and exciting therapy to patients in need,” said Dr. Alain Ptito, director of the department of psychology of the McGill University Health Centre and Coordinating Principal Investigator for the study. “The investigators and research teams from the Montreal Neurofeedback Center, Orlando Regional Medical Center, Oregon Health and Sciences University, Health Tech Connex, Inc., Virginia Commonwealth University, MedStar National Rehabilitation Hospital and University of Wisconsin – Madison are pleased with the execution of this study and look forward to further analysis and publication of the results.”
     
    “This is a very exciting and promising milestone for our Company, patients and the healthcare community,” added Helius’ CEO, Philippe Deschamps. “Our next steps include compiling the clinical evidence produced from this registrational trial and previous studies investigating the PoNS treatment, as well as verifying and validating product design improvements and manufacturing to be included in our regulatory application. We are working to submit our 510(K) application to the U.S. FDA in the first half of 2018, with clearance anticipated in the second half of 2018.”
     
    Helius is building upon almost 40 years of scientific research on neuromodulation, early pilot projects and case studies performed at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin in Madison. Most recently, a study at the University was conducted to evaluate what happens when responders to PoNS Therapy stop treatment. The results showed that, on average, subjects with compromised balanced who restored vestibular function to normal levels after 14 weeks, maintained their improvements even after 12 weeks of wash-out.
     
    The company followed up this news with an additional release in response to inquires about the data. This release provided clarification on the clinical trial results and confirmed the company’s intention to include traumatic brain injury registrational and long-term treatment trial data to support its application for clearance by the FDA.
     
    Philippe Deschamps, chief executive officer of Helius, stated, “The data showed participants who received PoNS Therapy experienced average SOT score improvements double to triple the increase that would be expected with physical therapy alone in a much shorter timeframe. The company is excited to finalize and submit its regulatory dossier to the FDA.” 
     
    Registrational TBI Trial
    Background Information:
     
    • Sensory Organization Test (SOT) was the measurement tool used in the trial to assess balance. It is a reliable, reproducible, referenced metric and recognized as a measure of clinically significant changes in trials measuring balance.
    • SOT Composite Score is a 0 to 100-point scale where zero means the patient cannot balance unaided and 100 implies perfect balance.
    • An average SOT score for a neurologically intact adult is 70 – 80 and a change in score of 8 points is considered clinically significant. The mean baseline score for subjects in the trials was about 40, representing a population with a profound loss of balance.
    • According to medical literature, subjects with chronic balance disorders caused by mild to moderate TBI have historically demonstrated limited response to physical therapy alone, with typical increases in SOT scores of 8-13 points over a 6-9 month period of time.
     
    Study Design:
     
    • The registrational trial was a randomized, double blind, multicenter clinical study designed to determine if a high frequency pulse (HFP) version of the investigational PoNS Therapy was superior to a low frequency pulse (LFP) version of the PoNS Therapy, that was intended in the trial design to be non-therapeutic. The LFP stimulus was detectable and was used to maintain blinding of study subjects and investigators.
    • Subjects:
      • Had suffered a mild to moderate TBI and had a chronic balance disorder.
      • Were at least one-year post injury and would, therefore, be unlikely to spontaneously recover their balance.
      • Had all completed balance rehabilitation therapy, documented by a healthcare professional to no longer provide benefit. Therefore, if they responded to investigational PoNS Therapy with either HFP or LFP, it would likely be due to the intervention of the PoNS Therapy.
    • The primary effectiveness endpoint in the trial was a responder analysis, comparing the HFP group to the LFP group. A responder was defined as a participant whose SOT score increased by more than 15 points, which is twice what is considered clinically significant and above what is typically seen in patients treated with PT alone. 
    • The secondary effectiveness endpoint in the trial was the mean change in composite SOT score at 2 and 5 weeks, compared to baseline.
     
    Our prospective statistical analysis plan contemplated the scenario where the LFP PoNS Therapy was observed to be therapeutically active in the trial which would make it more difficult to reach statistical significance in the between-group comparison for our primary endpoint. The statistical analysis plan also provided for combining the data for HFP and LFP into a single group to assess the secondary endpoints of mean increase in SOT scores from baseline to the score at 2 and 5 weeks post PoNS Therapy.
     
    Results of Registrational Trial:
     
    • The response rates in this study showed that 75.4 percent (HFP) and 60.7 percent (LFP) of participants had at least a 15-point change in SOT, having previously plateaued on PT alone. There was a trend to higher response rate in the HFP group when compared to the LFP group, but as between the groups, both groups showed a strong response. The p value was 0.081. Of note, the increase in SOT score in each group, 27.6 for HFP and 23.6 for LFP are markedly above what has been established for PT alone (8 - 13 points), a therapy all participants had previously undergone with no further benefit. Given this outcome, the next step of our statistical analysis plan was to combine the results for the two groups to ascertain if the mean change in the combined group would be significantly different from zero at the end of two weeks and five weeks of treatment. This would statistically assess whether the interventions in the HFP and LFP groups were positively therapeutic or not. The mean change was +18.3 at the two-week measurement point and +24.6 at week 5. Both measurements were statistically significant, p value <0.0005.
    • We assessed the change in SOT scores for each of the HFP and LFP groups and observed a statistically significant change p<0.025 when comparing the increase in SOT scores in both the week 2 and week 5 measurement points in both the HFP and LFP groups compared to the baseline scores.
    • The study met the primary and secondary safety endpoints. At baseline and post-PoNS therapy, the primary safety endpoint assessed falls and the secondary safety endpoint assessed headaches.
    • We did not observe any device related serious adverse events.
     
    Long-Term Treatment Trial
    The long-term treatment trial was performed at the University of Wisconsin-Madison. It was designed to investigate what happens when subjects in both HFP and LFP PoNS Therapy groups discontinued treatment for 12 weeks after receiving 14 weeks of therapy.
     
    • The results of the long-term trial were very similar to the results of the registrational trial.
    • There were no statistical differences between the HFP and LFP groups.
    • This study demonstrated that PoNS Therapy could help bring balance from profoundly disabled participants, to the normal range in 14 weeks of treatment and that this result was sustained without further therapy for another 12 weeks without any kind of prescribed therapy.
    • There were no device related serious adverse events in the long-term treatment trial.
     
    Plans for FDA Submission for Marketing Authorization
    First, it is critical to note that the planned route to market for the PoNS Therapy is as a class II medical device via the de novo classification process. This is novel technology for which there are currently no substantially equivalent devices being marketed in the US. During the pre-submission meeting with FDA, it was established that the investigational PoNS Therapy study to address balance symptoms in participants with mild to moderate TBI was a “Non-Significant Risk” device study.
     
    FDA will evaluate the probable benefit to health from the use of the device against any probable injury based upon a reasonable assurance of safety and effectiveness. There is a reasonable assurance that a device is effective when it can be determined by FDA, based upon valid scientific evidence, that in a significant portion of the target population, the intended use of the device will provide clinically significant results. We believe we have met this standard in the results of the two clinical trials reported on in this communication in participants that had significant balance disorder associated with their mild to moderate TBI.
     
    Second, the treatment of balance disorder after TBI is a significant health issue and represents an unmet medical need. We believe the results of these two clinical trials indicate that the investigational PoNS Therapy represents a promising opportunity to help patients and address a recognized unmet medical need.
     
    Helius also has accomplished the following steps to securing marketing authorization:
     
    1. Proven Quality Management Systems.The company obtained ISO 13485 certification in October 2016 and in September 2017, passed their annual audit with no issues. Helius has therefore satisfied this element.
    2. Design Verification:The company is engaged in a battery of tests to ensure the investigational PoNS device can be manufactured to the required quality. These tests, once successfully completed, will accompany submission to FDA.
     
    Conclusion
    We look forward to discussing the data with FDA to secure marketing clearance for the device. We now anticipate that our 510(K) application to the US FDA will be submitted in the first half of 2018, with clearance expected in the second half of 2018. The timing on our submission is based on our decision to use devices from our scale manufacturing line for our submission for clearance to enhance the quality and reliability of our commercial devices at launch.
    Related Searches
    • dr
    • iso 13485
    • fda
    • forward
    Related Knowledge Center
    • Neurological
    Suggested For You
    Breakthrough Device Designation Granted for New Neuromodulation Platform Breakthrough Device Designation Granted for New Neuromodulation Platform
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Improved Outcomes Proven With Insulet’s Omnipod 5 System Improved Outcomes Proven With Insulet’s Omnipod 5 System
    Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    FDA Approves TransMedics FDA Approves TransMedics' OCS Heart System for Donor Hearts
    RonovoRx RonovoRx's RenovoCath Earns New FDA 510(k)
    Bright Future Ahead for Renal Denervation Bright Future Ahead for Renal Denervation
    Acutus Medical Receives FDA Clearance for AcQMap 8 Software Upgrades Acutus Medical Receives FDA Clearance for AcQMap 8 Software Upgrades
    FDA Approves ZOLL FDA Approves ZOLL's remedē for Central Sleep Apnea
    Early Catheter Ablation of VT Outperforms Conventional Medical Therapy Early Catheter Ablation of VT Outperforms Conventional Medical Therapy
    Study: Human Oversight ECG Monitors Outperform AI-Dependent Monitoring Study: Human Oversight ECG Monitors Outperform AI-Dependent Monitoring
    Abbott Fined $160M to Resolve Medicare Diabetes Lawsuit Abbott Fined $160M to Resolve Medicare Diabetes Lawsuit
    Non-Profit Group Launches Initiative to Diversify Medtech Workforce Non-Profit Group Launches Initiative to Diversify Medtech Workforce
    BioFourmis BioFourmis' Digital Heart Failure Therapeutic Earns Breakthrough Status

    Related Breaking News

    • Breakthrough Device Designation Granted for New Neuromodulation Platform

      Breakthrough Device Designation Granted for New Neuromodulation Platform

      In a pilot study treating refractory epilepsy with Neuroelectrics’ Starstim platform, patients experienced a 44 percent median reduction in seizure frequency.
      Business Wire 09.22.21

    • Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech

      Electroducer Sleeve based on a medical technique called Direct Wire Pacing, which was invented by the company’s founder.
      Electroducer 09.21.21

    • Improved Outcomes Proven With Insulet’s Omnipod 5 System

      Improved Outcomes Proven With Insulet’s Omnipod 5 System

      Studies show the automated insulin delivery system improved HbA1c nearly one percentage point in kids and 0.60 percent in adolescents and adults.
      Business Wire 09.16.21


    • Patient Monitoring
      Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe

      Masimo Launches Single-Patient-Use rainbow SuperSensor in Europe

      Uses 12 LEDs to simultaneously offer 12 blood constituent parameters noninvasively and continuously.
      Business Wire 09.13.21

    • Vertigo Treatment Receives FDA Breakthrough Device Designation

      Vertigo Treatment Receives FDA Breakthrough Device Designation

      The device's developer—Otolith Labs—closes $3.3 million in seed financing.
      Business Wire 09.13.21


    Trending
    • The Power Of Leveraging Customer Relationships
    • Intermountain Healthcare & Siemens Healthineers Open 3 Tellica Outpatient Imaging Centers
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    • Magnetic Insight Announces $17 Million In Series B Funding
    • NHS England Selects Spectra Optia Apheresis System To Treat Sickle Cell Disease
    Breaking News
    • MPO's Most Read Stories This Week—June 25
    • Magnetic Insight Announces $17 Million in Series B Funding
    • BreatheSuite Adds Brad Fluegel to its Board
    • Labcorp Launches At-Home Collection Device for Diabetes Risk Testing
    • Thirona, Free Flow Medical Partner on COPD Solutions
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • OEMs Seek Molders Offering Timely Techniques
    • Robotic Surgery: Cutting Through to the Latest
    • Packaging, Sterilization Considerations Go Part and Parcel with Product Development
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Florida Food Products Acquires Javo
    Roquette Launches Nutralys Rice Protein
    New IADSA Chair Lauds Explorations of Supplementation in Healthcare Policy
    Coatings World

    Latest Breaking News From Coatings World

    The Southern Society for Coatings Technology's 84th Annual Technical Conference A Success
    PPG to Showcase Specialty Automotive, Aerospace Adhesives, Sealants at Adhesives & Bonding Expo
    PPG’s New Paint for a New Start Initiative to Transform 25-plus Schools Worldwide
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most Read Stories This Week—June 25
    Magnetic Insight Announces $17 Million in Series B Funding
    BreatheSuite Adds Brad Fluegel to its Board
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pierre Fabre and Lonza Enter Manufacturing Agreement
    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    Qosina Strengthens Aseptic Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Benefit Exec Joins Madison Reed's Board
    Peroni & Ellis Brooklyn Launch Fragrance Collection Inspired by Italian Spritz Cocktails
    Rhode Is Trending for June, Trendalytics Says
    Happi

    Latest Breaking News From Happi

    Wonder Curl Wins GlossWire's GlossPitch Competition
    Anti-aging Skincare Brand Vitabrid C12 Launches Bestsellers on Amazon
    Botanical Embedded Candles Can Be Fire Hazard, Says National Candle Association
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
    British Coatings Federation Posts Online History
    Orion Announces Price Increases, Reduced Payment Terms
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PCMC teams with IGT, Fujifilm makes big announcement and more
    Loftware recognized as 'AIDC Company of the Year'
    Schreiner MediPharm highlights sustainability of Needle-Trap technology
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Tranzonic Names VP of Supply Chain
    Ontex Climate Action Targets Approved by Science-Based Targets Initiative
    Suominen Test Center Assesses Biodegradability of Nonwovens
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—June 25
    3Spine Inc. Receives IDE Approval for U.S. Pivotal Clinical Trial
    Volume-Based Procurement to Reduce Chinese Orthopedic Market Value
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories
    NREL Names Jennifer Logan to Leadership Team as CFO
    National Grid Renewables Orders 2 GW of First Solar Modules

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login